Work

CRISPR/methotrexate-integrated strategy for TCR-T cell engineering with reduced chromosome 14 loss

Year: 2025

Type: article

Abstract: and in xenograft models. In conclusion, this integrated platform mitigates viral vector risks, alleviates concerns of CRISPR-associated genomic instability, and provides a good manufacturing practice (GMP)-compatible approach that may facilitate the development of safer adoptive TCR-T immunotherapies.

Source: Molecular Therapy — Methods & Clinical Development

DOI: 10.1016/j.omtm.2025.101635

Authors: Jian Xu, Lianghua Shen, Ziyu Chen, Changmeng Zhang, Xiaodan Ding, Qiaomei He, Xiao Zhou, Peiyao Jiang, Jiayu Liu, Lu Li, Jinan Fang, Fanlin Li, Liping Wan, Xueying Ding, Yuqin Yang, Xiaorui Wang, Pengran Wang, Xianmin Song, Yan Zhang

Institutions: Shanghai Jiao Tong University, Shanghai First People's Hospital, Science and Technology Commission of Shanghai Municipality, Shanghai Cell Therapy Research Institute

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,900

Funders: Science and Technology Commission of Shanghai Municipality, Wuhan University, Shanghai Hospital Development Center, National Key Research and Development Program of China, National Key Research and Development Program of China Stem Cell and Translational Research

Awards: G4282659261, G4484374375, G481556571, G7117004588, G941720531

OpenAlex ID: W4416230763

FWCI: 0.363

Cites: 38

Cited by: 1

Related to: